Microlab technology offers a new clinical paradigm for rapid and low cost 'screen out' and 'screen in' capability at the point of care and puts the physician back in control by not forcing the patient to a specialist for diagnosis.

This paradigm also reduces the liability profile for pharmaceutical companies and lowers the cost of treatment for the insurance companies. In the end, this provides faster diagnosis and better outcome for patients.

To do this, MicroLab keeps the chip simple and low cost by building the control and measurement components into the processing instrumentation. With this approach we can deliver a highly differentiated product that precisely matches both the collaborator's and their customer's requirements.

We focus on the analytical end point required by the end user. Our tools approach insures that the chip we design and ship will perform specific tasks without compromise.